Investment Insights for Cell Therapy Manufacture

Introduction

Commercial sustainability extends beyond manufacturing cost. It encompasses reliable supply, scalable operations, regulatory compliance, reimbursement, patient access and the ability to generate sufficient returns to sustain ongoing investment.

Many of the decisions that determine commercial outcomes are made during process development long before product approval is achieved. The purpose of this article is to highlight manufacturing and investment planning insights that can influence those decisions.

For patient-specific therapies, manufacturing considerations cannot be separated from clinical development. Changes to the manufacturing process may alter the final product and can create significant comparability and regulatory challenges later in development. Manufacturing readiness therefore needs to evolve alongside the clinical programme rather than follow it. (Refs 1, 2)

The consequence is that many commercial outcomes are influenced by decisions made during Phase 1 development. Process selection, automation strategy, facility architecture and scale-out plans all have the potential to affect future manufacturing cost, patient access and investment requirements.

The following examples illustrate how manufacturing studies and commercial modelling can help identify priorities that might otherwise be overlooked while development teams focus on the immediate demands of clinical development.

Cost of Goods Analysis Challenges Assumptions

Early cost modelling often overturns intuitive assumptions regarding labour, automation and facility utilisation. A sustainable cost of goods is required both to support patient access and to provide a return on the substantial investment needed to develop and commercialise a therapy. (Refs 3, 4)

The first insight from cost modelling is that automation changes where costs occur rather than eliminating them. Labour costs may be reduced, but automation introduces equipment, development and maintenance costs while reagents and disposables remain significant contributors to treatment cost.

The second insight is that increasing throughput often has a greater influence on direct manufacturing cost than the choice between manual and automated processing. Capital and facility costs are spread across a larger number of treatments while reagent costs remain largely unchanged.

This does not imply automation lacks value. These cost models do not include the consequences of batch variations, investigations, process deviations and operational disruption. The primary benefit of automation may therefore be improved process reliability and reduced operational risk rather than direct labour savings.

Some costs, such as development expenditure and facility investment, are spread across increasing patient numbers as sales grow. Consumables, reagents and many single-use components remain closely tied to each treatment. Decisions that lock in expensive materials during early development may therefore become permanent commercial cost burdens.

Finally, sensitivity analysis helps identify which assumptions matter most. In many patient-specific therapies, reagent costs dominate the commercial outcome. Labour, facility and equipment costs may be important, but they often have a smaller influence than expected.

Cost modelling frequently demonstrates that efforts to reduce labour costs can distract attention from the larger economic impact of reagents and consumables.

Decisions that lock in expensive reagents, low yields or complex consumable assemblies during early development may become permanent commercial cost burdens. These assumptions deserve rigorous challenge during phase 1 process design.  (Refs 3, 4)

Why it matters

The largest cost drivers are not always where expected. Early analysis helps direct development resources toward the factors that most strongly influence commercial viability.

Patient-Specific Therapies need to be transferrable to CMO’s

Unlike conventional biopharmaceutical products, patient-specific therapies do not scale by increasing batch size. They scale by replicating manufacturing capability across facilities and jurisdictions. (Ref 5)

Non-intuitively patient-specific products must scale-out to other facilities to access the patient population.

Patients gain access to therapies through physicians, hospitals and healthcare networks operating within their local healthcare systems. Reliance upon a single global manufacturing site may substantially increase logistics complexity while diminishing perceptions of local availability, resilience and long-term supply security.

CMO’s are ideally placed to service their local health networks, and know how to meet local compliance standards with exisiting facilities and trained personnel. Commercially these attributes speed the transition to income relative to a build-out for every site.

The Commercial Advantage of a Transferable Manufacturing System

The ability to transfer a manufacturing process into existing facilities such as CMO’s can have a larger impact on commercial success than modest differences in manufacturing cost.

Cost of goods analysis often suggests that dedicated manufacturing facilities eventually achieve the lowest cost per treatment.

Cost modelling suggests that building and owning dedicated facility capacity can reduce manufacturing cost by approximately €3,000 per patient at relevant production volumes. However, this unit-cost advantage must be weighed against the capital required to create that capacity before demand is confirmed.

Using existing facility capacity such as CMO’s may therefore be commercially attractive even when the cost per patient is higher. The advantage is not primarily lower cost of goods; it is the ability to:

• defer or avoid facility capital expenditure.
• add capacity closer to demonstrated demand, and
• reduce investor exposure to over-building.

CMO’s can also accelerate market entry, providing access to trained personnel and established quality systems expanding patient access to the therapy.

Discounted cash flow analysis suggests that access to existing manufacturing capacity suchn as a CMO can provide a meaningful commercial benefit before considering patient revenue. In one example, deferring approximately €29 million of facility capital until capacity was required increased NPV by approximately €5.6 million when capital expenditure would otherwise precede revenue by three years.

Scenario	NPV benefit
Facility capital deployed with demand	$0M (baseline)
Capital committed 1 year before revenue	$1.6M
Capital committed 2 years before revenue	$3.5M
Capital committed 3 years before revenue	$5.6M

Relative to the estimated $29.3 million facility investment, delaying capital expenditure until capacity was required created an NPV benefit equivalent to approximately 20% of the facility capital value.

The larger commercial benefit arises when existing facilities allow patient treatments to commence sooner. Earlier patient access translates directly into earlier revenue generation, which may exceed the value created by delaying capital expenditure alone.

Together these effects produced a significantly stronger commercial outcome than could be inferred from manufacturing cost alone.

For patient-specific therapies, scale-out is achieved by replicating manufacturing capability rather than increasing batch size. Manufacturing systems that can be transferred into existing facilities benefit from a larger pool of potential deployment sites, can expand geographically with less capital investment and can begin treating patients sooner. (Refs 5, 7)

As a result, a manufacturing strategy with a slightly higher treatment cost may generate superior commercial returns if it enables faster deployment, earlier revenue generation and reduced investment risk.

Facility transferability is therefore a commercial attribute as well as a manufacturing attribute.

The lowest-cost manufacturing strategy is not always the strongest investment strategy.

Navigating Reimbursement and Patient demand uncertainty

Manufacturing cost establishes the minimum viable treatment price. Reimbursement determines the treatment revenue that healthcare systems may be willing to support. Commercial success requires these values to overlap.

To gain insight to the commercial merits of the investment:

• Patient demand An estimate of the potential patient demand is needed.  How many patients per year might receive the therapy, and how will demand evolve as clinical adoption grows?

• Time to market How long will the clinical trials take, how many years until the therapy is approved for market? A discounted cash flow highlights sensitivity to time delays.  What are the consequences of schedule delays?

These estimates can be assembled into a commercial assessment. One approach is to apply a Monte Carlo simulation that incorporates uncertainty in patient demand, reimbursement, development timelines, operating costs and capital investment into an NPV (net present value) calculation. (Ref 6) The advantage is the estimates are clearly described for debate, and a sensitivity analysis can be used to highlight changing influences as confidence in the cost components improves.

This tool can be used to explore how manufacturing cost, reimbursement, and delay to market impact the break-even (npv = 0) for the investment.

Delay to Market

The analysis assumes a ten-year investment horizon and 15% discount factor. Delays to market reduce the available revenue-generating period while increasing the discounting of future cash flows. As a result, a greater proportion of the forecast patient population must be treated, or a higher reimbursement must be achieved, to reach the same commercial outcome.

If the commercial plan forecasts 10,000 patients over the ten-year investment horizon, the example row on the right shows the proportion of those patients that must be treated to achieve a break-even NPV assuming a reimbursement of $40,000 per treatment.

Without delay, approximately 3,300 patients (33%) are required to recover the development, facility and manufacturing investment. A one-year delay increases this requirement to approximately 5,100 patients (51%). A two-year delay increases the requirement to approximately 9,600 patients (96%).

The reason is simple. Delays reduce the available revenue-generating period while increasing the discounting of future cash flows. Commercial success therefore requires either a larger patient population or higher reimbursement per treatment.

Mapping break-even reimbursement

The table extends the analysis across a range of reimbursement estimates. It can be read as a lookup table: if actual patient demand is expected to be around 30% of the business-case forecast, the table identifies the reimbursement required to achieve break-even under different delay-to-market scenarios.

Patient benefit alone does not guarantee adoption. Commercial success requires alignment between treatment cost, healthcare funding and investor returns.

The analysis demonstrates how reimbursement levels, patient demand and delays to market can have a profound effect on the commercial robustness of a therapy, independent of its technical success. (Ref 6)

Conclusion

Commercial cell therapy development inevitably involves uncertainty.

Patient demand, reimbursement, development timelines and manufacturing costs are all imperfectly understood during early clinical development. A manufacturing strategy is still required despite this uncertainty.

The objective is not to predict the future perfectly.

The objective is to create a basis for discussion and decision making. The process highlights commercial priorities that can easily be overlooked while development teams focus on the immediate demands of clinical development.

Cost modelling challenges assumptions regarding labour, automation and facility utilisation. Transferability analysis highlights the commercial value of manufacturing systems that can be deployed into existing facilities. Discounted cash flow analysis demonstrates the importance of reimbursement, patient demand and time to market.

Together these tools provide a practical method for evaluating manufacturing decisions long before commercial production begins.

For patient-specific therapies, the strongest commercial strategy may not be the one with the lowest manufacturing cost. It may be the strategy that enables reliable scale-out, faster patient access and efficient deployment of capital.

Commercial success depends on more than manufacturing economics. It depends on creating a pathway from promising science to sustainable patient impact.

References

1. FDA – Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products
2. Comparability Tales Roadmap
3. COG Roadmap for Cell Therapies
4. What Does Cell Therapy Manufacturing Cost?
5. Overcoming Operational and Regulatory Challenges in Autologous Cell-Therapy Facilities
6. A Model-Based Approach to Address the Commercialisation of Autologous Cell Therapies
7. The CMO Dilemma